Pyrroloquinoline

Oxidative stress is the core inducing factor for the progression of various neurodegenerative diseases and metabolic syndromes. Pyrroloquinoline quinone (PQQ), as a new type of small-molecule substance belonging to the redox cofactor category, can scavenge excess free radicals by regulating the Nrf2 antioxidant pathway, while promoting the synthesis of nerve growth factors and improving the energy metabolism efficiency of mitochondria. Preclinical and clinical studies have shown that it can be applied in the fields of cognitive dysfunction improvement, myocardial ischemia protection, germ cell viability enhancement, etc. It can also serve as a nutritional supplement component to provide metabolic support for sub-healthy populations, middle-aged and elderly populations, and patients in the rehabilitation period of specific diseases.

At present, the global market size related to pyrroloquinoline quinone has exceeded 320 million US dollars, with a compound annual growth rate of 11.7% in the past three years. The demand growth is mainly concentrated in two sectors: food for special medical purposes and neurological drug R&D. In terms of the competitive landscape, the upstream API supply is dominated by Chinese and Japanese enterprises, among which the production capacity of Chinese manufacturers accounts for more than 65% of the total global supply. As its compound patent has entered the public domain, the development enthusiasm for generic and innovative preparations continues to rise, and nearly 20 clinical trial applications for related preparations have been accepted in China.

The original research enterprise of pyrroloquinoline quinone is Mitsubishi Gas Chemical Company, Inc. of Japan, with the original brand name BioPQQ. Its core compound patent expired globally in 2018. The main dosage form approved by the original research company is dietary supplement tablet, with common specifications including 10mg and 20mg. It has been included in the FDA Dietary Supplement Ingredient Directory, and has not been included in the chemical reference preparation directory in China for the time being. In terms of API registration, at present, 8 domestic enterprises have completed the registration of pyrroloquinoline quinone APIs in CDE, all of which are in the status of "A (approved for use in marketed preparations)". A number of food for special medical purposes and dietary supplement products containing pyrroloquinoline quinone have been approved for marketing. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO can provide a full series of impurity reference standards for pyrroloquinoline quinone, covering a total of 12 process impurities and degradation impurities. Most products are available in stock. Spot orders placed before 16:00 can be shipped on the same day. All products comply with the relevant regulatory requirements of the Chinese Pharmacopoeia and FDA, and can fully meet the full-process needs of API enterprises in process development, quality research, registration and declaration, etc.